A phase 3, randomized, three-arm, double-blind, active controlled, parallel group, multicenter trial to evaluate the safety and efficacy of muraglitazar in combination with metformin compared to glimepiride in combination with metformin in subjects with type 2 diabetes who have inadequate glycaemic control on metformin therapy alone
Latest Information Update: 06 May 2022
At a glance
- Drugs Muraglitazar (Primary) ; Glimepiride
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Bristol-Myers Squibb; Merck Sharp & Dohme Corp.
- 22 Oct 2005 New trial record.